Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

The landscape of cancer cell line metabolism.

Li H, Ning S, Ghandi M, Kryukov GV, Gopal S, Deik A, Souza A, Pierce K, Keskula P, Hernandez D, Ann J, Shkoza D, Apfel V, Zou Y, Vazquez F, Barretina J, Pagliarini RA, Galli GG, Root DE, Hahn WC, Tsherniak A, Giannakis M, Schreiber SL, Clish CB, Garraway LA, Sellers WR.

Nat Med. 2019 May;25(5):850-860. doi: 10.1038/s41591-019-0404-8. Epub 2019 May 8.

2.

Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss.

Liu H, Golji J, Brodeur LK, Chung FS, Chen JT, deBeaumont RS, Bullock CP, Jones MD, Kerr G, Li L, Rakiec DP, Schlabach MR, Sovath S, Growney JD, Pagliarini RA, Ruddy DA, MacIsaac KD, Korn JM, McDonald ER 3rd.

Nat Med. 2019 Jan;25(1):95-102. doi: 10.1038/s41591-018-0302-5. Epub 2018 Dec 17.

PMID:
30559422
3.

Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways.

Podrini C, Rowe I, Pagliarini R, Costa ASH, Chiaravalli M, Di Meo I, Kim H, Distefano G, Tiranti V, Qian F, di Bernardo D, Frezza C, Boletta A.

Commun Biol. 2018 Nov 16;1:194. doi: 10.1038/s42003-018-0200-x. eCollection 2018.

4.

mTORC1 Upregulation Leads to Accumulation of the Oncometabolite Fumarate in a Mouse Model of Renal Cell Carcinoma.

Drusian L, Nigro EA, Mannella V, Pagliarini R, Pema M, Costa ASH, Benigni F, Larcher A, Chiaravalli M, Gaude E, Montorsi F, Capitanio U, Musco G, Frezza C, Boletta A.

Cell Rep. 2018 Jul 31;24(5):1093-1104.e6. doi: 10.1016/j.celrep.2018.06.106.

5.

Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.

Zhao Q, Manning JR, Sutton J, Costales A, Sendzik M, Shafer CM, Levell JR, Liu G, Caferro T, Cho YS, Palermo M, Chenail G, Dooley J, Villalba B, Farsidjani A, Chen J, Dodd S, Gould T, Liang G, Slocum K, Pu M, Firestone B, Growney J, Heimbach T, Pagliarini R.

ACS Med Chem Lett. 2018 Jun 11;9(7):746-751. doi: 10.1021/acsmedchemlett.8b00182. eCollection 2018 Jul 12.

6.

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor.

Cho YS, Levell JR, Liu G, Caferro T, Sutton J, Shafer CM, Costales A, Manning JR, Zhao Q, Sendzik M, Shultz M, Chenail G, Dooley J, Villalba B, Farsidjani A, Chen J, Kulathila R, Xie X, Dodd S, Gould T, Liang G, Heimbach T, Slocum K, Firestone B, Pu M, Pagliarini R, Growney JD.

ACS Med Chem Lett. 2017 Sep 18;8(10):1116-1121. doi: 10.1021/acsmedchemlett.7b00342. eCollection 2017 Oct 12.

7.

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

McDonald ER 3rd, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, Belur D, Castelletti D, Frias E, Gampa K, Golji J, Kao I, Li L, Megel P, Perkins TA, Ramadan N, Ruddy DA, Silver SJ, Sovath S, Stump M, Weber O, Widmer R, Yu J, Yu K, Yue Y, Abramowski D, Ackley E, Barrett R, Berger J, Bernard JL, Billig R, Brachmann SM, Buxton F, Caothien R, Caushi JX, Chung FS, Cortés-Cros M, deBeaumont RS, Delaunay C, Desplat A, Duong W, Dwoske DA, Eldridge RS, Farsidjani A, Feng F, Feng J, Flemming D, Forrester W, Galli GG, Gao Z, Gauter F, Gibaja V, Haas K, Hattenberger M, Hood T, Hurov KE, Jagani Z, Jenal M, Johnson JA, Jones MD, Kapoor A, Korn J, Liu J, Liu Q, Liu S, Liu Y, Loo AT, Macchi KJ, Martin T, McAllister G, Meyer A, Mollé S, Pagliarini RA, Phadke T, Repko B, Schouwey T, Shanahan F, Shen Q, Stamm C, Stephan C, Stucke VM, Tiedt R, Varadarajan M, Venkatesan K, Vitari AC, Wallroth M, Weiler J, Zhang J, Mickanin C, Myer VE, Porter JA, Lai A, Bitter H, Lees E, Keen N, Kauffmann A, Stegmeier F, Hofmann F, Schmelzle T, Sellers WR.

Cell. 2017 Jul 27;170(3):577-592.e10. doi: 10.1016/j.cell.2017.07.005.

8.

Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.

Levell JR, Caferro T, Chenail G, Dix I, Dooley J, Firestone B, Fortin PD, Giraldes J, Gould T, Growney JD, Jones MD, Kulathila R, Lin F, Liu G, Mueller A, van der Plas S, Slocum K, Smith T, Terranova R, Touré BB, Tyagi V, Wagner T, Xie X, Xu M, Yang FS, Zhou LX, Pagliarini R, Cho YS.

ACS Med Chem Lett. 2016 Dec 16;8(2):151-156. doi: 10.1021/acsmedchemlett.6b00334. eCollection 2017 Feb 9.

9.

Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.

Xie X, Baird D, Bowen K, Capka V, Chen J, Chenail G, Cho Y, Dooley J, Farsidjani A, Fortin P, Kohls D, Kulathila R, Lin F, McKay D, Rodrigues L, Sage D, Touré BB, van der Plas S, Wright K, Xu M, Yin H, Levell J, Pagliarini RA.

Structure. 2017 Mar 7;25(3):506-513. doi: 10.1016/j.str.2016.12.017. Epub 2017 Jan 26.

10.

In Silico Modeling of Liver Metabolism in a Human Disease Reveals a Key Enzyme for Histidine and Histamine Homeostasis.

Pagliarini R, Castello R, Napolitano F, Borzone R, Annunziata P, Mandrile G, De Marchi M, Brunetti-Pierri N, di Bernardo D.

Cell Rep. 2016 Jun 7;15(10):2292-2300. doi: 10.1016/j.celrep.2016.05.014. Epub 2016 May 26.

11.

ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.

Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M, McAllister G, Hoffman G, Ramadan N, Hartung A, Feng Y, Kipp DR, Quinn C, Fodor M, Baird J, Schoumacher M, Meyer R, Deeds J, Buchwalter G, Stams T, Keen N, Sellers WR, Brown M, Pagliarini RA.

Elife. 2016 May 16;5. pii: e13964. doi: 10.7554/eLife.13964.

12.

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.

Mavrakis KJ, McDonald ER 3rd, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, Yu J, McAllister G, Stump M, deBeaumont R, Ho S, Yue Y, Liu Y, Yan-Neale Y, Yang G, Lin F, Yin H, Gao H, Kipp DR, Zhao S, McNamara JT, Sprague ER, Zheng B, Lin Y, Cho YS, Gu J, Crawford K, Ciccone D, Vitari AC, Lai A, Capka V, Hurov K, Porter JA, Tallarico J, Mickanin C, Lees E, Pagliarini R, Keen N, Schmelzle T, Hofmann F, Stegmeier F, Sellers WR.

Science. 2016 Mar 11;351(6278):1208-13. doi: 10.1126/science.aad5944. Epub 2016 Feb 11.

13.

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.

Pagliarini R, Shao W, Sellers WR.

EMBO Rep. 2015 Mar;16(3):280-96. doi: 10.15252/embr.201439949. Epub 2015 Feb 13. Review.

14.

The novolactone natural product disrupts the allosteric regulation of Hsp70.

Hassan AQ, Kirby CA, Zhou W, Schuhmann T, Kityk R, Kipp DR, Baird J, Chen J, Chen Y, Chung F, Hoepfner D, Movva NR, Pagliarini R, Petersen F, Quinn C, Quinn D, Riedl R, Schmitt EK, Schitter A, Stams T, Studer C, Fortin PD, Mayer MP, Sadlish H.

Chem Biol. 2015 Jan 22;22(1):87-97. doi: 10.1016/j.chembiol.2014.11.007. Epub 2014 Dec 24.

15.

TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Mounir Z, Lin F, Lin VG, Korn JM, Yu Y, Valdez R, Aina OH, Buchwalter G, Jaffe AB, Korpal M, Zhu P, Brown M, Cardiff RD, Rocnik JL, Yang Y, Pagliarini R.

Oncogene. 2015 Jul;34(29):3815-25. doi: 10.1038/onc.2014.308. Epub 2014 Sep 29.

PMID:
25263440
16.

Overexpression of the activated form of the AtAREB1 gene (AtAREB1ΔQT) improves soybean responses to water deficit.

Leite JP, Barbosa EG, Marin SR, Marinho JP, Carvalho JF, Pagliarini RF, Cruz AS, Oliveira MC, Farias JR, Neumaier N, Guimarães FC, Yoshida T, Kanamori N, Fujita Y, Nakashima K, Shinozaki KY, Desidério JA, Nepomuceno AL.

Genet Mol Res. 2014 Aug 15;13(3):6272-86. doi: 10.4238/2014.August.15.10.

17.

Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.

Chen Y, Chen J, Yu J, Yang G, Temple E, Harbinski F, Gao H, Wilson C, Pagliarini R, Zhou W.

J Biol Chem. 2014 Jul 4;289(27):18914-27. doi: 10.1074/jbc.M114.574053. Epub 2014 May 15.

18.

IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.

Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X, Slocum KL, Pu M, Lin F, Vickers C, Joud-Caldwell C, Chung F, Yin H, Handly ED, Straub C, Growney JD, Vander Heiden MG, Murphy AN, Pagliarini R, Metallo CM.

Cancer Res. 2014 Jun 15;74(12):3317-31. doi: 10.1158/0008-5472.CAN-14-0772-T. Epub 2014 Apr 22.

19.

A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein.

Pop MS, Stransky N, Garvie CW, Theurillat JP, Hartman EC, Lewis TA, Zhong C, Culyba EK, Lin F, Daniels DS, Pagliarini R, Ronco L, Koehler AN, Garraway LA.

Mol Cancer Ther. 2014 Jun;13(6):1492-502. doi: 10.1158/1535-7163.MCT-13-0689. Epub 2014 Apr 15.

20.

Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.

Grassian AR, Pagliarini R, Chiang DY.

Curr Opin Gastroenterol. 2014 May;30(3):295-302. doi: 10.1097/MOG.0000000000000050. Review.

PMID:
24569570
21.

Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth.

Chen J, Chung F, Yang G, Pu M, Gao H, Jiang W, Yin H, Capka V, Kasibhatla S, Laffitte B, Jaeger S, Pagliarini R, Chen Y, Zhou W.

Oncotarget. 2013 Dec;4(12):2502-11.

22.

Targeting HSF1 sensitizes cancer cells to HSP90 inhibition.

Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J, Chung F, Korn J, Ruddy D, Guo R, McLaughlin ME, Feng F, Zhu P, Stegmeier F, Pagliarini R, Porter D, Zhou W.

Oncotarget. 2013 Jun;4(6):816-29.

23.

A genome-scale modeling approach to study inborn errors of liver metabolism: toward an in silico patient.

Pagliarini R, di Bernardo D.

J Comput Biol. 2013 May;20(5):383-97. doi: 10.1089/cmb.2012.0276. Epub 2013 Mar 6.

24.

Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).

Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, Korpal M, Astley H, Gitterman D, Henley T, Howes R, Levell J, Korn JM, Pagliarini R.

J Biol Chem. 2012 Dec 7;287(50):42180-94. doi: 10.1074/jbc.M112.417832. Epub 2012 Oct 4.

25.

Population-based surveillance for invasive pneumococcal disease and pneumonia in infants and young children in Goiânia, Brazil.

Andrade AL, Oliveira R, Vieira MA, Minamisava R, Pessoa V Jr, Brandileone MC, Alves SL, Alfieri F, Pagliarini R, Moraes JC, Gray S, Rodgers GL.

Vaccine. 2012 Feb 27;30(10):1901-9. doi: 10.1016/j.vaccine.2011.12.012. Epub 2011 Dec 15.

PMID:
22178522
26.

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N.

Cancer Res. 2010 Sep 1;70(17):6804-14. doi: 10.1158/0008-5472.CAN-10-0409. Epub 2010 Aug 10.

27.

Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.

Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N.

Science. 2009 Sep 18;325(5947):1555-9. doi: 10.1126/science.1174229. Epub 2009 Aug 6.

28.

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.

Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3964-9. doi: 10.1073/pnas.0813333106. Epub 2009 Feb 18.

29.

Antimicrobial defense shows an abrupt evolutionary transition in the fungus-growing ants.

Hughes WO, Pagliarini R, Madsen HB, Dijkstra MB, Boomsma JJ.

Evolution. 2008 May;62(5):1252-7. doi: 10.1111/j.1558-5646.2008.00347.x. Epub 2008 Feb 8.

PMID:
18266984
30.

Basement membrane remodeling is essential for Drosophila disc eversion and tumor invasion.

Srivastava A, Pastor-Pareja JC, Igaki T, Pagliarini R, Xu T.

Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2721-6. Epub 2007 Feb 14.

31.

Loss of cell polarity drives tumor growth and invasion through JNK activation in Drosophila.

Igaki T, Pagliarini RA, Xu T.

Curr Biol. 2006 Jun 6;16(11):1139-46.

32.

The colorectal microRNAome.

Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B, Velculescu VE.

Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3687-92. Epub 2006 Feb 27.

33.

A genetic screen in Drosophila for metastatic behavior.

Pagliarini RA, Xu T.

Science. 2003 Nov 14;302(5648):1227-31. Epub 2003 Oct 9.

34.

Analyzing the function of tumor suppressor genes using a Drosophila model.

Pagliarini RA, Quiñones AT, Xu T.

Methods Mol Biol. 2003;223:349-82. Review. No abstract available.

PMID:
12777740
35.

Improvement of the slide hemagglutination test for rapid Chagas' disease screening in epidemiological surveys.

Nagasse-Sugahara TK, Hoshino-Shimizu S, Pagliarini RC, Celeste BJ.

Braz J Med Biol Res. 1996 May;29(5):623-8.

PMID:
9033812
36.

Mononuclear cell cytotoxicity in rats with Walker 256 tumor.

Maria DA, Pagliarini RC, Mistrone RJ, Pozzi DH, Zyngier S.

Braz J Med Biol Res. 1994 Jun;27(6):1343-6.

PMID:
7894346

Supplemental Content

Loading ...
Support Center